Steve Connor
Corporate Officer/Principal en AM-Pharma BV .
Origen de la red de primer grado Steve Connor.
Entidad | Tipo de entidad | Industria | |
---|---|---|---|
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands.
16
| Holding Company | Biotechnology | 16 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Steve Connor a través de su red personal
Empresa | Sector | Personas relacionadas | Puesto principal |
---|---|---|---|
NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
IsoTis, Inc.
IsoTis, Inc. Medical SpecialtiesHealth Technology IsoTis, Inc. designs, manufactures and sells bone graft substitutes and other devices. The company was founded on November 15, 2006 and is headquartered in Plainsboro, NJ. | Medical Specialties | Corporate Officer/Principal | |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Generic | Director/Board Member | |
Arthur D. Little, Inc.
Arthur D. Little, Inc. Miscellaneous Commercial ServicesCommercial Services Arthur D. Little, Inc. engages in the provision of management consulting services. It specializes in strategy and organization, operations management, technology and innovation management, corporate finance, and global carbon advisory serving corporations and organizations worldwide. The firm serves the automotive, healthcare, information, chemicals, consumer goods, retail, manufacturing, and transportation industries. The company was founded by Arthur Dehon Little and Roger Griffin in October 1886 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
LSP Management Group BV
LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies. | Investment Managers | Founder Private Equity Analyst | |
VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Organon International, Inc.
Organon International, Inc. Pharmaceuticals: MajorHealth Technology Organon International, Inc. manufactures and markets pharmaceutical products. It develops therapeutics in the fields such as gynecology, fertility, osteoporosis, and anesthesia. The company was founded in 1923 and is located in Roseland, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Biotechnology | Director/Board Member | |
University of Amsterdam | College/University | Undergraduate Degree Graduate Degree | |
Yamanouchi Pharma SA
Yamanouchi Pharma SA Pharmaceuticals: MajorHealth Technology Yamanouchi Pharma SA manufactures and distributes pharmaceutical products. It operates as a subsidiary of Astellas Pharma, Inc. The company was founded in 1993 and is headquartered in Madrid, Spain. | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Leiden | College/University | Doctorate Degree Doctorate Degree | |
University of Utrecht | College/University | Doctorate Degree Graduate Degree | |
AM-Pharma Holding BV
AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member Chief Executive Officer Director/Board Member Chief Operating Officer Corporate Officer/Principal Corporate Officer/Principal | |
Otsuka America Pharmaceutical, Inc.
Otsuka America Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Otsuka America Pharmaceutical, Inc. manufactures and supplies pharmaceutical products. It develops drugs for neuroscience, cardiovascular, and gastrointestinal treatments. The company was founded in 1989 and is headquartered in Rockville, MD. | Pharmaceuticals: Major | Chief Executive Officer | |
AKEBIA THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
CELLDEX THERAPEUTICS, INC. | Medical/Nursing Services | Director/Board Member | |
Sanifit Therapeutics SA
Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Chairman Director/Board Member | |
Kurma Partners SA
Kurma Partners SA Investment ManagersFinance Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France. | Investment Managers | Corporate Officer/Principal Private Equity Investor | |
Manchester Business School | College/University | Masters Business Admin | |
Grünenthal NV
Grünenthal NV Pharmaceuticals: MajorHealth Technology Grünenthal NV engages in the manufacture of pharmaceuticals and drugs. The company was founded in 1946 and is headquartered in Sint-Stevens-Woluwe, Belgium. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
HeatMatrix Group BV
HeatMatrix Group BV Building ProductsProducer Manufacturing HeatMatrix Group BV develops and manufactures plastic heat exchangers for waste heat recovery from industrial corrosive flue gas. The firm’s heat exchangers can be used in the petrochemicals and chemicals, bio-energy, food, agricultural, and paper industries. Its products include air pre-heater, hybrid exchanger, gas to liquid, and in situ cleaning system. The company was founded by Erik van den Berg in 2008 and is headquartered in Geldermalsen, the Netherlands. | Building Products | Founder | |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Biotechnology | Chief Executive Officer | |
SoniVie Ltd.
SoniVie Ltd. Medical SpecialtiesHealth Technology SoniVie Ltd. engages in the development of a system for the treatment of pulmonary hypertension. Its products include Therapeutic Intra-Vascular Ultrasound (TIVUS) system, an intravascular, catheter-based technology that can cause denervation of nerves surrounding blood vessels and other structures like the bronchus. The company was founded by Moshe Arkin in 2014 and is headquartered in Rosh Haayin, Israel. | Medical Specialties | Director/Board Member | |
PHARVARIS N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Step Pharma SAS
Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Pharmaceuticals: Major | Chairman Chairman | |
Axonics, Inc. (New York) | Director/Board Member | ||
Imcheck Therapeutics SAS
Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
PROVENTION BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
LAVA THERAPEUTICS N.V. | Biotechnology | Founder Corporate Officer/Principal | |
Grey Wolf Therapeutics Ltd.
Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Arvelle Therapeutics International GmbH
Arvelle Therapeutics International GmbH BiotechnologyHealth Technology Arvelle Therapeutics GmbH provides treatment for patients suffering form CNS disorders. The company was founded by Ilise Lombrado, Gregory Mark Weinhoff and Mark Altmeyer and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member Founder | |
Tridek-One Therapeutics SAS
Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Miscellaneous Commercial Services | Director/Board Member | |
Vico Therapeutics BV
Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Pharvaris GmbH
Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
EQT Life Sciences Group BV
EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor Private Equity Investor | |
Lead Pharma Holding BV
Lead Pharma Holding BV Pharmaceuticals: MajorHealth Technology Lead Pharma Holding BV develops small-molecule drugs for the treatment of autoimmune diseases and cancer. It specializes in medicinal, computational, and protein chemistry, x-ray crystallography, cell biology, and integration x-omics. The company was founded by Ad van Gorp, Leon de Windt, and Pieter Doevendans in 2007 and is headquartered in Oss , the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Gamma Développement
Gamma Développement Miscellaneous Commercial ServicesCommercial Services Gamma Developpement engages in the financial industry providing business strategies and financial support solutions. The company was founded by Jean-Marc Duminil on May 3, 2010 and is headquartered in Combaillaux, France. | Miscellaneous Commercial Services | Director/Board Member | |
Winch Italy Holdings 1 SARL | Corporate Officer/Principal | ||
EPG Investment Partners SA | Chairman |
Estadísticas
Internacional
Países Bajos | 14 |
Estados Unidos | 10 |
Francia | 10 |
Suiza | 6 |
Reino Unido | 5 |
Sectorial
Health Technology | 32 |
Commercial Services | 6 |
Consumer Services | 6 |
Finance | 4 |
Health Services | 3 |
Operativa
Director/Board Member | 127 |
Corporate Officer/Principal | 40 |
Chairman | 28 |
Independent Dir/Board Member | 20 |
Chief Executive Officer | 12 |
Las relaciones más conectadas
Insiders | |
---|---|
Raphaël Wisniewski | 45 |
Martijn Kleijwegt | 33 |
Russell Greig | 31 |
Rémi Droller | 29 |
Geert-Jan Mulder | 17 |
Mark Altmeyer | 16 |
Andrea van Elsas | 16 |
Rita Jain | 14 |
Erik van den Berg | 13 |
Felice Verduyn-van Weegen | 9 |
Ton Adang | 8 |
Jaques Arend | 6 |
Juliane Bernholz | 2 |
Ravindra Mehta | 2 |
Patrick Honoré | 2 |
- Bolsa de valores
- Insiders
- Steve Connor
- Conexiones Empresas